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EvaluaƟon therapy aŌer 3 months c
In case the paƟent is in remission (normalized hematological parameters, normalized and/or stabilized kidney funcƟon and proteinuria, normal blood) adjustment of eculizumab therapy can be considered 
Monitoring aŌer therapy adjustment
Regular workup at every hospital visit is required or in case of disconƟnuaƟon aŌer 1,2,3,6,9 &12 months aŌer withdrawal. Between hospital visits, dipsƟck analysis and/or blood pressure (aim for p50 in children or below 130/80mmHg in adults) monitoring 3 Ɵmes per week at home is advised. Fig. 1 Treatment algorithm. After adequate exclusion of other causes of thrombotic microangiopathy (TMA) such as thrombocytopenic purpura (TTP), Shiga toxin-producing Escherichia coli-hemolytic uremic syndrome (STEC-HUS), or secondary TMA and in patients with strong suspicion of atypical hemolytic uremic syndrome (aHUS), eculizumab treatment should be started within 24 h after presentation. When the patient is stable and in remission, withdrawal or tapering can be considered, depending on patient characteristics (see Fig. 2 ). After therapy adjustment, strict monitoring is essential. NB in case of antibodies against complement factor H, a different treatment protocol has to be initiated as described by Loirat et al. In adults with first episode of aHUS in native kidney, treatment with plasma exchange (PE) for 4 days (high volume PE with 1.5 plasma volume) is advised to allow diagnosis of secondary causes of aHUS. Adolescents may be considered adults [33] . After exclusion of secondary causes of aHUS and if the patient does not show a favorable response after 4 days of PE, treatment should be switched to eculizumab. Starting treatment with eculizumab within 7 days after presentation in PE-resistant patients was effective in the clinical trials [32] . In case the patient is PE sensitive, PE should be tapered and discontinued in the course of 1 month [9, 10] . c, Improvement of platelets and lactate dehydrogenase (LDH) is expected within 2-4 weeks. If no response, consider alternative diagnosis or inefficacy of eculizumab (C5 polymorphism
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